SEC Form 4 · accession 0001144204-18-062682
Fortress Biotech, Inc. · FBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Malcolm Hoenlein
Director
Period of report
Jan 1, 2018
Accepted (ET)
Nov 30, 2018 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001429260
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 1, 2018 | A | 50,000 | $0.00 | A | 285,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1One-third of the shares will vest on each January 1, 2019, 2020 and 2021, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
- F2The total holdings include 50,000 shares underlying deferred share units that were previously reported in Table II.